Crown Bioscience Expands Genomics and Next Generation Sequencing (NGS) Capabilities To Streamline Translational Biomarker Discovery Workflows
전체 맥락을 이해하기 위해서는 본문 보기를 권장합니다.
"With our range of validated services, we can help drug developers improve the accuracy, sensitivity and speed at which they progress their new agent programs via discovery of MOAs and predictive biomarkers," said Henry Li, PhD, chief scientific officer at CrownBio. "This type of multi-omics data is essential to understand the clinical populations that respond to anticancer agents and progress cancer treatments."
"Quality downstream applications are key to maximizing the full potential of in vivo study results, including our wealth of historical model and treatment data," said Sheng Guo, PhD, head of bioinformatics at CrownBio. "These are leveraged by a highly experienced team and a proprietary, published algorithm to provide important biomarker discovery and drug mechanism probing services."
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
SAN DIEGO -- Businesswire -- Crown Bioscience, a JSR Life Sciences company, today announced the expansion of their state-of-the-art NGS capabilities, together with the launch of proprietary NGS panel services, providing increased opportunities for pharmaceutical partners to better understand drug mechanisms of action (MOA) and to develop predictive biomarkers for their investigational drug candidates.
The newly built, comprehensive suite of NGS capabilities provides clients with a streamlined multi-omics workflow of high-quality services, enabling full genomic understanding, including global gene expression, mutations, and genomic structures. This is a significant addition to CrownBio’s current preclinical and translational services, allowing clients greater insight into disease mechanisms, drug MOAs, and responder patient populations, to ultimately accelerate successful development of effective therapies.
The expanded services have been established at the Company’s Center of Translational Science in Suzhou, China, to meet increased client demand for whole genome sequencing (WGS), including Illumina’s Novaseq 6000 and BGI’s MGISEQ-2000 second generation sequencing platform. PacBio’s third generation Sequel Ⅱ sequencing platform allows for high throughput, high accuracy long-read NGS, and Bionano’s Saphyr® Genome Imaging enables large structural variant analysis and genome mapping. Comprehensive data analysis pipelines have also been built, together offering highly sensitive genome assembly and discovery algorithms.
“With our range of validated services, we can help drug developers improve the accuracy, sensitivity and speed at which they progress their new agent programs via discovery of MOAs and predictive biomarkers,” said Henry Li, PhD, chief scientific officer at CrownBio. “This type of multi-omics data is essential to understand the clinical populations that respond to anticancer agents and progress cancer treatments.”
In addition to the validated commercial platforms, CrownBio has also developed various powerful biomedical applications using NGS platforms, including NGS panels for bio-sample authentication, contamination detection and quantification, mouse tumor microenvironment profiling and metagenomic sequencing services for microbiome analysis. Custom NGS services are also available for clients who wish to utilize CrownBio’s expertise and large model biobank.
“Quality downstream applications are key to maximizing the full potential of in vivo study results, including our wealth of historical model and treatment data,” said Sheng Guo, PhD, head of bioinformatics at CrownBio. “These are leveraged by a highly experienced team and a proprietary, published algorithm to provide important biomarker discovery and drug mechanism probing services.”
These NGS services are available for client use immediately including our newly launched mouse I/O profiling targeted RNA-seq panel. The panel will allow deep profiling of the immunogenomics of murine tumor-immune interactions through the measurement of 1080 transcripts from a single sample.
About Crown Bioscience Inc.
Crown Bioscience, a JSR Life Sciences company, is a global drug discovery and development service company providing translational platforms to advance oncology, inflammation, and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates. For more information, visit:
· https://www.crownbio.com · https://www.jsrlifesciences.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210110005013/en/
이 뉴스는 기업·기관·단체가 뉴스와이어를 통해 배포한 보도자료입니다.
출처:Crown Bioscience Inc.
보도자료 통신사 뉴스와이어(www.newswire.co.kr) 배포
Copyright © 뉴스와이어. 무단전재 및 재배포 금지.
- 삶과 죽음의 순환을 녹여낸 전시 ‘마인드붐 2024 : 발 아래 처음, 하늘 아래 마지막’ 성황리 개
- 금천구시설관리공단 ‘주민이 선정한 공단 BEST 사업 선호도 조사’ 실시 - 뉴스와이어
- 교직원공제회, 암치료·간병보장 강화한 신상품 출시 - 뉴스와이어
- LG생활건강 에어 칫솔, 레드닷 ‘베스트 오브 베스트’ 선정 - 뉴스와이어
- 꽃을 통해 사람을 이야기하는 힐링 국악 콘서트 ‘화담풍류’ 김포다도박물관에서 열려 - 뉴스
- GS25, 물가안정 PB ‘리얼프라이스’ 매출 350억원 돌파… 초가성비 라면·조미김 라인업 강화 - 뉴
- Kinaxis Named a Customers’ Choice in the Gartner® 2024 Voice of the Customer for Supply Chain Planning Solutions - 뉴스와
- KB국민은행, 20만좌 한정 ‘KB스타적금Ⅱ’ 출시 - 뉴스와이어
- 키넥시스, 공급망 솔루션에 대한 가트너® 2024 보이스 업 커스터머에서 커스터머스 초이스로 선
- 포스코인터내셔널, 주주친화정책과 디지털화를 선도하며 한국 IR대상 최우수상 수상 쾌거 - 뉴